COSM

Cosmos Health Inc.

$0.20

-26.14%
SectorHealthcareIndustryMedical DistributionCountryGreece

Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin).

Source: Yahoo Finance
AI summary

Price & performance

1M-17.2%
3M+34.3%
YTD-45.5%
1Y-73.3%
52-week range—
Beta1.44
Full chart and returns against a benchmark

Q-Score

39/ 100

Quality against peers; 50 is the peer median.

Growth45
Risk42
Performance36
Valuation52
Profitability43
Leverage34
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$65.3M+19.9%
Net income-$19.1M
Net margin-29.3%+0.4 pts
Historical fundamentals

Red flags in filings

3active red flags
Going-concern doubtApr 15, 2026
Late filing noticeAug 14, 2026
Exchange listing noticeDec 18, 2025
Filings, findings and the timeline

Revenue exposure

Regions, segments, customers and suppliers

Valuation

COSMIndustryP/E—28.60P/S0.270.25EV/EBITDA—17.46P/B0.960.96PEG—0.72
Dividend yield0.00%
Every valuation metric